The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback